Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
28.72 EUR | +1.13% | +7.85% | +20.01% |
12:55pm | Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024 | MT |
10:20am | AstraZeneca upbeat as cancer drugs underpin sales growth | AN |
Sales 2024 | 1,602B 10.29B 9.61B | Sales 2025 * | 1,747B 11.23B 10.48B | Capitalization | 9,068B 58.28B 54.38B |
---|---|---|---|---|---|
Net income 2024 | 201B 1.29B 1.2B | Net income 2025 * | 181B 1.16B 1.09B | EV / Sales 2024 | 5.72 x |
Net cash position 2024 * | 556B 3.57B 3.33B | Net cash position 2025 * | 599B 3.85B 3.59B | EV / Sales 2025 * | 4.85 x |
P/E ratio 2024 * |
54.2
x | P/E ratio 2025 * |
50.4
x | Employees | 17,435 |
Yield 2024 * |
0.96% | Yield 2025 * |
1.1% | Free-Float | 97.04% |
Latest transcript on Daiichi Sankyo Co., Ltd.
1 day | +1.14% | ||
1 week | +7.85% | ||
Current month | -1.75% | ||
1 month | +1.04% | ||
3 months | +11.08% | ||
6 months | +15.42% | ||
Current year | +20.01% |
Managers | Title | Age | Since |
---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
Hiroyuki Okuzawa
PSD | President | 61 | 17-03-31 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 21-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 19-05-31 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 19-05-31 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 29.27 | +3.06% | 135 |
24-04-24 | 28.4 | +2.16% | 150 |
24-04-23 | 27.8 | +0.40% | 65 |
24-04-22 | 27.69 | -3.22% | 150 |
24-04-19 | 28.61 | +5.42% | 356 |
Delayed Quote Deutsche Boerse AG, April 25, 2024 at 02:02 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.61% | 660B | |
+22.95% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+12.77% | 219B | |
-9.65% | 196B | |
+6.46% | 199B | |
-8.75% | 149B |
- Stock Market
- Equities
- 4568 Stock
- D4S Stock